导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.15% | 1385/4773 |
| 近一周 | -2.81% | 4664/5467 |
| 近一月 | 0.42% | 370/5421 |
| 近一季 | 3.52% | 480/5238 |
| 近半年 | -1.89% | 2127/4931 |
| 近一年 | 5.36% | 1544/4400 |
| 近两年 | 32.87% | 2155/2954 |
| 近三年 | 21.45% | 1411/2253 |
| 成立以来 | 97.45% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.83% 654/4961 |
-9.19% 3946/5312 |
- - |
- - |
| 2025 | 6.53% 2957/4813 |
-2.28% 2869/3635 |
3.04% 1185/4076 |
2.98% 3776/4524 |
2.75% 864/4813 |
| 2024 | 14.50% 1041/3463 |
3.45% 571/2808 |
1.97% 421/3014 |
9.28% 2708/3129 |
-0.68% 1497/3463 |
| 2023 | -1.63% 525/2656 |
3.00% 1281/2280 |
-2.25% 575/2385 |
1.39% 313/2515 |
-3.64% 748/2655 |
| 2022 | 6.45% 14/2207 |
5.55% 32/1919 |
5.78% 825/2016 |
-1.51% 25/2113 |
-3.21% 1842/2208 |
| 2021 | 17.06% 248/1822 |
5.22% 118/1255 |
3.68% 960/1330 |
12.37% 99/1466 |
-4.51% 1486/1822 |
| 2020 | - - |
- - |
- - |
13.18% 342/1164 |
7.48% 709/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4796 | 32.41% |
| 港股通药 | 0.9109 | 32.37% |
| 万家中证港股通创新药ETF | 1.6293 | 32.25% |
| 景顺长城中证港股通创新药ETF | 1.6918 | 32.17% |
| 天弘恒生沪深港创新药精选50ETF | 0.8599 | 32.08% |
| 港股医疗 | 0.9703 | 31.90% |
| 港医疗 | 0.9212 | 31.83% |
| 港股通医疗ETF工银 | 0.9798 | 31.81% |
| 港股通医疗ETF华宝 | 0.9918 | 31.64% |
| 万家中证港股通创新药ETF发起式联接A | 1.4193 | 31.06% |
| 西部利得国企红利指数增强C VS. 长安沪深300非周期A(740101) |